In the world of cancer genomics, mutational hotspots and cancer drivers are used somewhat interchangeably. "It was common knowledge... that if you see a site [mutated] in many cancers, that site is a driver," Gad Getz told BioWorld. But Getz, who is director of the Cancer Genome Computational Analysis Group at the Broad Institute of MIT and Harvard, and his team argue that the conventional wisdom is incorrect.